logo
logo
Sign in

Global Neuroendocrine Tumor Treatment Market Dynamics

avatar
Ben Wood
Global Neuroendocrine Tumor Treatment Market Dynamics

Peptide receptor radionuclide therapy (PRRT) is a newer treatment option for NETs that uses radioactive isotopes to selectively target somatostatin receptors on the tumor cells. PRRT has been shown to be effective in controlling symptoms and improving survival in patients with advanced NETs. Lutathera, a PRRT drug, was approved by the FDA in 2018 for the treatment of gastroenteropancreatic NETs. Other PRRT drugs, such as 177Lu-Dotatate, are currently in clinical trials for the treatment of NETs.


Immunotherapy is another emerging treatment option for NETs. Immunotherapy works by activating the patient's immune system to recognize and attack cancer cells. Checkpoint inhibitors are a type of immunotherapy that has shown promise in the Neuroendocrine Tumor Treatment Market of some types of cancer, including melanoma and lung cancer. Clinical trials are currently underway to evaluate the efficacy of checkpoint inhibitors in the treatment of NETs.


North America is anticipated to witness significant growth in the global neuroendocrine tumor treatment market over the forecast period, owing to growing adoption of advanced techniques and increasing technological advancements.

Major players operating in the global neuroendocrine tumor treatment market are Progenics Pharmaceuticals, BoehringerIngelheim International GmbH, IpsenPharma, AVEO Oncology, Pfizer, Inc., Novartis AG, Hutchison MediPharma Limited, and Tarveda Therapeutics.


Read More:

https://knackersblogger.blogspot.com/2023/03/global-neuroendocrine-tumor-treatment.html


collect
0
avatar
Ben Wood
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more